Cardio4D

Founders, Backgrounds, and Bench

Cardio4D is led by co-founder and CTO Thuy Pham. Other team members are not surfaced in the public research.

One source, partially checked -- Founder role supported by third-party database; other team details are not publicly available.

Company Overview

Cardio4D operates as an early-stage health technology venture focused on structural heart planning. The company is headquartered in Lake Forest, California [RocketReach, retrieved 2024]. Its public presence is anchored by a functional website and a LinkedIn company page, which outline its mission to transform cardiac imaging workflows [Cardio4d.net, retrieved 2024] [LinkedIn, retrieved 2024].

Thuy Pham is publicly identified as the company's Chief Technology Officer [RocketReach, retrieved 2024]. Pham also holds the CTO role at Sutra Medical, Inc. [Sutra Medical, retrieved 2026]. The founding date and incorporation details are not publicly available.

One source, partially checked -- Company location and co-founder role supported by a single third-party database; product claims sourced directly from company materials.

The Product and the Stack

The core proposition is a software platform that aims to convert a standard cardiac CT scan into a dynamic, predictive model for planning structural heart interventions. According to the company's website, the process begins with a secure upload of a patient's CT data, which the system processes using AI to automate the reconstruction of a 3D anatomical model [Cardio4d.net, retrieved 2024]. This model forms the basis of a 'predictive digital twin,' which is animated through physics-based simulations to forecast biomechanical responses [Cardio4d.net, retrieved 2024]. The workflow is cloud-based, with the goal of providing 'mechanistic insights' to help clinicians evaluate procedural risks.

The platform's differentiation rests on the integration of two computational layers: an AI-driven reconstruction engine for segmentation and 3D modeling, and a physics-based modeling layer for biomechanical simulation. The company presents these as three core capabilities: automated anatomy reconstruction, functional prediction, and a unified, secure cloud workflow [Cardio4d.net, retrieved 2024].

One source, partially checked -- Product claims are sourced solely from the company's website. Technical capabilities and workflow are described but lack third-party technical validation.

The Market They Are Entering

The structural heart planning market is driven by an aging population and a shift towards minimally invasive, patient-specific procedures. A relevant analog is the global transcatheter aortic valve replacement (TAVR) market, valued at approximately $5.6 billion in 2022 and projected to expand at a compound annual growth rate of 10.2% from 2023 to 2030 [Grand View Research, 2023].

Metric	Value
TAVR Market 2022	$5.6B
Projected CAGR 2023-2030	10.2%

One source, partially checked -- Market sizing is based on an analogous segment report; direct TAM for the company's product is not publicly available.

The Competitive Field

Cardio4D enters a specialized niche within the medical imaging and cardiac planning software market. The company's positioning centers on creating predictive, physics-based digital twins from standard CT scans specifically for structural heart procedures.

Cardio4D’s opportunity is to become the default pre-operative planning platform for structural heart interventions, including TAVR and mitral valve repair. The company’s approach targets a workflow bottleneck where physicians currently rely on 2D imaging and mental extrapolation [Cardio4d.net, retrieved 2024]. The regulatory and commercial progress of competitor inHeart, which has received FDA clearance for its digital twin technology, validates the category’s feasibility.

Scenario	What happens	Catalyst	Why it's plausible
Standard-of-Care Adoption	Cardio4D becomes a recommended tool within major heart center protocols for TAVR planning.	A pivotal clinical study demonstrates superior outcomes or efficiency.	Competitor inHeart has established a clinical validation template.
Technology Licensing	The core AI reconstruction engine is licensed to a major imaging OEM for integration into their scanner software suite.	A partnership announcement with an imaging hardware manufacturer.	The product’s reliance on standard CT scan data aligns with OEMs’ strategies to add AI-powered software value.

One source, partially checked -- The product vision and market context are drawn from the company's website and a competitor's known regulatory progress.